# Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

> **NCT00903292** · NA · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib (Tarceva)
- **DRUG:** pemetrexed (Alimta)

## Key facts

- **NCT ID:** NCT00903292
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2009-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903292, "Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00903292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*